Isabelle Chemin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5835898/publications.pdf

Version: 2024-02-01

99 papers	3,381 citations	136950 32 h-index	155660 55 g-index
110 all docs	110 docs citations	110 times ranked	3933 citing authors

#	Article	IF	Citations
1	Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. British Journal of Cancer, 2008, 99, 143-150.	6.4	183
2	High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. Journal of Hepatology, 2001, 34, 447-454.	3.7	158
3	Hepatitis B virus induced hepatocellular carcinoma. Cancer Letters, 2009, 286, 52-59.	7.2	158
4	Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. Journal of Hepatology, 2011, 54, 705-715.	3.7	153
5	Clinical impact of occult HBV infections. Journal of Clinical Virology, 2005, 34, S15-S21.	3.1	150
6	Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 683-689.	2.5	148
7	Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. The Lancet Global Health, 2016, 4, e559-e567.	6.3	137
8	Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells. PLoS ONE, 2011, 6, e26315.	2.5	132
9	Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. , 2000, 86, 1-7.		128
10	Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Molecular Carcinogenesis, 1994, 11, 74-80.	2.7	94
11	Occult HBV infection may represent a major risk factor of nonâ€response to antiviral therapy of chronic hepatitis C. Journal of Medical Virology, 2007, 79, 1075-1081.	5.0	87
12	Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. Journal of Medical Virology, 2004, 73, 508-515.	5.0	81
13	Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. Hepatology, 2017, 66, 703-716.	7.3	78
14	Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Letters, 2009, 286, 80-88.	7.2	70
15	Discovery of naturally occurring transmissible chronic hepatitis B virus infection amongMacaca fascicularisfrom mauritius island. Hepatology, 2013, 58, 1610-1620.	7.3	69
16	Liver-directed gene transfer: a linear polyethylenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. Journal of Viral Hepatitis, 1998, 5, 369-375.	2.0	66
17	Use of a TT virus ORF1 recombinant protein to detect anti-TT virus antibodies in human sera. Journal of General Virology, 2000, 81, 2949-2958.	2.9	56
18	Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis, 2010, 31, 1475-1482.	2.8	55

#	Article	IF	Citations
19	DNA Methylation of Hepatitis B Virus (HBV) Genome Associated with the Development of Hepatocellular Carcinoma and Occult HBV Infection. Journal of Infectious Diseases, 2010, 202, 700-704.	4.0	55
20	Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. Journal of Hepatology, 2018, 69, 776-784.	3.7	55
21	Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology, 2002, 35, 1215-1224.	7.3	54
22	Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA. Antimicrobial Agents and Chemotherapy, 2008, 52, 3068-3073.	3.2	54
23	Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis. Transfusion, 1992, 32, 215-220.	1.6	49
24	Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Therapy, 2001, 8, 874-881.	4.5	47
25	Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. Tumor Biology, 2012, 33, 325-336.	1.8	47
26	Detection of Polyadenylated RNA in Hepatitis B Virus-Infected Peripheral Blood Mononuclear Cells by Polymerase Chain Reaction. Journal of Infectious Diseases, 1991, 163, 996-1000.	4.0	44
27	Role of silent hepatitis B virus in chronic hepatitis B surface antigen(â^') liver disease. Antiviral Research, 2001, 52, 117-123.	4.1	43
28	Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. Journal of Hepatology, 2009, 51, 824-825.	3.7	41
29	Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. Journal of Infection, 2011, 63, 66-75.	3.3	40
30	PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitrohepatocellular carcinoma models. BMC Cancer, 2014, 14, 603.	2.6	40
31	Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA). Journal of Virological Methods, 2013, 193, 653-659.	2.1	39
32	TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia. Carcinogenesis, 2012, 33, 1219-1224.	2.8	38
33	Correlation between HBV DNA detection by polymerase chain reaction and pre-S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections. Journal of Medical Virology, 1991, 33, 51-57.	5.0	35
34	Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver International, 1999, 19, 81-87.	3.9	33
35	Variability in the Precore and Core Promoter Regions of HBV Strains in Morocco: Characterization and Impact on Liver Disease Progression. PLoS ONE, 2012, 7, e42891.	2.5	33
36	Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy. Journal of Clinical Virology, 2005, 33, 150-157.	3.1	31

#	Article	IF	Citations
37	New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. Journal of Clinical Microbiology, 1992, 30, 1111-1119.	3.9	31
38	Genotype determination in Moroccan hepatitis B chronic carriers. Infection, Genetics and Evolution, 2008, 8, 306-312.	2.3	29
39	Interactions between hepatitis B virus and aflatoxin B1: effects on p53 induction in HepaRG cells. Journal of General Virology, 2012, 93, 640-650.	2.9	26
40	Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus. Hepatology, 2021, 73, 861-864.	7.3	26
41	Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clinical Infectious Diseases, 2020, 70, 1442-1452.	5.8	25
42	Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes. PLoS ONE, 2017, 12, e0179697.	2.5	24
43	Hepatitis B virus American genotypes: Pathogenic variants ?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 825-835.	1.5	24
44	Viral spliced RNA are produced, encapsidated and reverse transcribed during in Vivo woodchuck hepatitis virus infection. Virology, 1992, 190, 193-200.	2.4	21
45	Occult <scp>HBV</scp> infection in Morocco: from chronic hepatitis to hepatocellular carcinoma. Liver International, 2014, 34, e144-50.	3.9	21
46	Alteration of splicing factorsâ€™ expression during liver disease progression: impact on hepatocellular carcinoma outcome. Hepatology International, 2019, 13, 454-467.	4.2	21
47	Hepatitis B virus preS2Î”38â€“55 variants: A newly identified risk factor for hepatocellular carcinoma. JHEP Reports, 2020, 2, 100144.	4.9	21
48	Hepatitis B virus replication in primary macaque hepatocytes: Crossing the species barrier toward a new small primate model. Hepatology, 2010, 51, 1954-1960.	7.3	20
49	Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells. Journal of Immunology, 2018, 201, 2331-2344.	0.8	18
50	Genome-wide 5-hydroxymethylcytosine (5hmC) emerges at early stage of in vitro differentiation of a putative hepatocyte progenitor. Scientific Reports, 2020, 10, 7822.	3.3	18
51	Experimental transfection of Macaca sylvanus with cloned human hepatitis B virus. Journal of General Virology, 2002, 83, 1645-1649.	2.9	18
52	Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAgâ^' patients coinfected or not with HIV or HCV. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 373-383.	1.5	17
53	Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antiviral Therapy, 2009, 14, 131-135.	1.0	17
54	Demonstration of woodchuck hepatitis virus infection of peripheral blood mononuclear cells by flow cytometry and polymerase chain reaction. Journal of General Virology, 1992, 73, 123-129.	2.9	14

#	Article	IF	Citations
55	High prevalence of hepatitis B virus genotype E in Northern Madagascar indicates a Westâ€African lineage. Journal of Medical Virology, 2010, 82, 1515-1526.	5.0	14
56	Implementation of an inâ€house quantitative realâ€time polymerase chain reaction method for Hepatitis B virus quantification in West African countries. Journal of Viral Hepatitis, 2016, 23, 897-904.	2.0	14
57	Toll-like receptor 9 polymorphisms and Hepatitis B virus clearance in Moroccan chronic carriers. Gene, 2019, 687, 212-218.	2.2	14
58	Unusual presentation of hepatitis B serological markers in an Amerindian community of Venezuela with a majority of occult cases. Virology Journal, 2011, 8, 527.	3.4	13
59	Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand. Hepatitis Research and Treatment, 2011, 2011, 1-9.	2.0	13
60	Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development. Future Oncology, 2010, 6, 21-23.	2.4	12
61	PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achillesâ€™ heel?. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101553.	1.5	11
62	Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins. Cancer Letters, 2007, 248, 81-88.	7.2	9
63	Update on hepatocellular carcinoma breakthroughs: Poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 137-142.	1.5	9
64	Prevalence and Clinical Significance of Occult Hepatitis B Infection in The Gambia, West Africa. Journal of Infectious Diseases, 2022, 226, 862-870.	4.0	8
65	Integration of hepatitis B virus DNA into p21-activated kinase 3 (PAK3) gene in HepG2.2.15 cells. Virus Genes, 2020, 56, 168-173.	1.6	7
66	Cas9-targeted nanopore sequencing reveals epigenetic heterogeneity after de novo assembly of native full-length hepatitis B virus genomes. Microbial Genomics, 2021, 7, .	2.0	7
67	A New Viral Agent, SEN Virus (SENV), Has Been Detected in Patients from Several Countries: The Pathogenic Role of SENV in Coinfections with Hepatitis B Virus or Hepatitis C Virus Should Be Investigated. Journal of Infectious Diseases, 2002, 185, 710-710.	4.0	6
68	Pretreatment Predictive Factors for Hepatitis C Therapy Outcome: Relevance of Anti-E1E2 Antibodies Compared to Ip-10 and Il28B Genotypes. Antiviral Therapy, 2013, 18, 1027-1032.	1.0	6
69	Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101502.	1.5	6
70	Hepatitis B Virus Genotype Study in West Africa Reveals an Expanding Clade of Subgenotype A4. Microorganisms, 2021, 9, 623.	3.6	6
71	Possible prevention of chronic hepatitis B by early interferon therapy. Journal of Hepatology, 1990, 11, S95-S99.	3.7	5
72	Double hepatitis B virus infection in a patient with HIV/hepatitis C virus coinfection and â€˜anti-HBc aloneâ€™ as serological pattern. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 623-627.	2.9	5

#	Article	IF	Citations
73	Occult B infection in the Brazilian northeastern region: a preliminary report. Brazilian Journal of Infectious Diseases, 2008, 12, 310-312.	0.6	5
74	LP26 : Nucleic acid polymers are efficient in blocking hepatitis delta virus entry in vitro. Journal of Hepatology, 2015, 62, S276.	3.7	5
75	P0556 : Antiviral effects of nucleic acid polymers on hepatitis B virus infection. Journal of Hepatology, 2015, 62, S523.	3.7	3
76	Clinical utility of the 'Determine HBsAg' Point-of-Care Test for Diagnosis of Hepatitis B Surface Antigen in Africa. Expert Review of Molecular Diagnostics, 2022, 22, 497-505.	3.1	3
77	HBV continuum of care using community- and hospital-based screening interventions in Senegal: Results from the PROLIFICA programme. JHEP Reports, 2022, 4, 100533.	4.9	3
78	Editorial foreword special issue â€œHepatocellular Carcinoma â€“ A Worldwide Translational Approachâ€• Cancer Letters, 2009, 286, 3-4.	7.2	2
79	P177: Nucleic acid polymers are efficient in blocking hepatitis delta virus entry in vitro. Journal of Viral Hepatitis, 2015, 22, 107-107.	2.0	2
80	Clinical utility of quantifying hepatitis B surface antigen in African patients with chronic hepatitis B. Journal of Viral Hepatitis, 2021, 28, 1003-1010.	2.0	2
81	Immunohistochemical Detection of HCV Proteins in Liver Tissue. Methods in Molecular Biology, 2009, 510, 25-30.	0.9	2
82	What is really ongoing during occult HBV reactivation?. Hepatology, 2006, 43, 195-195.	7.3	1
83	Evolution of Hepatitis B and C serum markers: a still challenging issue. Liver International, 2011, 31, 905-907.	3.9	1
84	The Molecular Pathology and Clinical Impact of HBV Genetic Variability. Hepatitis Research and Treatment, 2011, 2011, 1-1.	2.0	1
85	Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 699-704.	1.5	1
86	Alternative splicing regulation during the course of liver disease. Journal of Hepatology, 2018, 68, S130.	3.7	1
87	HBV and the importance of TLR9 on B cell responses. AIMS Allergy and Immunology, 2017, 1, 124-137.	0.5	1
88	Direct cloning and expression of PCR amplified DNA and RNA sequences: Application to the hepadnaviruses nucleocapsid proteins. Journal of Virological Methods, 1993, 42, 337-344.	2.1	0
89	Experimental transfection of macaca sylvanus with cloned human hepatitis B virus. Journal of Hepatology, 2002, 36, 23.	3.7	0
90	Occult HBV infections worsen the course of hepatitis infection. Journal of Hepatology, 2002, 36, 103.	3.7	0

#	Article	IF	Citations
91	351 Frizzled-7 is commonly expressed by cancerous hepatocytes in virus and non-virus related human hepatocellular carcinomas: Correlations with pathological features and Î²-catenin/p53 mutation status. Journal of Hepatology, 2006, 44, S134.	3.7	0
92	[420] DOES HEPATITIS B VIRUS ESCAPE INNATE IMMUNITY BY SILENCING PLASMACYTOID DENDRITIC CELLS RESPONSE?. Journal of Hepatology, 2007, 46, S161.	3.7	0
93	Epigenetic effects of hepatitis B virus and their role in hepatocellular carcinoma. European Journal of Cancer, Supplement, 2008, 6, 197.	2.2	0
94	Cancer letters special issue hepatocellular carcinoma featuring the guest editors. Cancer Letters, 2009, 286, 1-2.	7.2	0
95	P1090 VIROLOGICAL PROFILES OF HEPATITIS B VIRUS (HBV)-INFECTED AFRICAN PATIENTS TREATED WITH TENOFOVIR. Journal of Hepatology, 2014, 60, S441.	3.7	0
96	Virological profiles of hepatitis B virus (HBV)-infected African patients treated with tenofovir. International Journal of Infectious Diseases, 2014, 21, 8.	3.3	0
97	Development and validation of a simple score to select HBV-infected patients for antiviral therapy in Africa. Journal of Hepatology, 2017, 66, S686.	3.7	0
98	Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 313-318.	1.5	0
99	Occult Hepatitis B infection is frequent and a risk factor of advanced liver disease in The Gambia, West Africa. Journal of Hepatology, 2018, 68, S485-S486.	3.7	0